Provided by Tiger Trade Technology Pte. Ltd.

Rezolute, Inc.

4.64
+0.26005.94%
Post-market: 4.57-0.0700-1.51%17:40 EDT
Volume:2.20M
Turnover:10.06M
Market Cap:446.80M
PE:-6.21
High:4.69
Open:4.33
Low:4.32
Close:4.38
52wk High:11.46
52wk Low:1.07
Shares:96.29M
Float Shares:72.51M
Volume Ratio:1.03
T/O Rate:3.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7467
EPS(LYR):-0.7467
ROE:-59.04%
ROA:-35.32%
PB:4.44
PE(LYR):-6.21

Loading ...

Rezolute highlights Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism at ENDO meeting

Reuters
·
Jun 17

Rezolute Is Maintained at Buy by Guggenheim

Dow Jones
·
Jun 15

Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Vericel (VCEL)

TIPRANKS
·
Jun 10

Craig-Hallum Keeps Their Hold Rating on Rezolute (RZLT)

TIPRANKS
·
Jun 05

Rezolute flags Phase 3 sunRIZE top-line results for ersodetug in congenital hyperinsulinism at ENDO 2026

Reuters
·
Jun 04

Rezolute Raised to Market Outperform From Market Perform by Citizens

Dow Jones
·
Jun 03

Wedbush Adjusts Price Target on Rezolute to $6 From $5, Maintains Outperform Rating

MT Newswires Live
·
Jun 03

Rezolute Is Maintained at Buy by BTIG

Dow Jones
·
Jun 03

Rezolute upgraded to Outperform from Market Perform at Citizens

TIPRANKS
·
Jun 03

Rezolute price target raised to $6 from $5 at BTIG

TIPRANKS
·
Jun 03

Analysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY)

TIPRANKS
·
Jun 03

Rezolute price target raised to $14 from $10 at Maxim

TIPRANKS
·
Jun 03

Rezolute Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 02

BUZZ-U.S. STOCKS ON THE MOVE-Dollar General, Vera, Amtech Systems

Reuters
·
Jun 02

Rezolute Says 6 Participants Meet Responder Criterion in Phase 3 Tumor Hyperinsulinism Trial

MT Newswires Live
·
Jun 02

BUZZ-U.S. STOCKS ON THE MOVE-Microchip Technology, Marvell Technology, Generac

Reuters
·
Jun 02

BUZZ-Rezolute climbs after positive trial results for low blood sugar treatment

Reuters
·
Jun 02

Rezolute says 6 of 8 patients meet primary endpoint in Phase 3 upLIFT trial of ersodetug for tumor hyperinsulinism

Reuters
·
Jun 02

Rezolute - Topline Results for Uplift Study Expected in Second Half of 2026

THOMSON REUTERS
·
Jun 02

Rezolute - All 6 Responders Achieve Complete Discontinuation of Intravenous Glucose Requirements

THOMSON REUTERS
·
Jun 02